Pharma BD Deal Intelligence
A $20.1B hostile-turned-friendly acquisition that transformed Sanofi from a diversified pharma conglomerate into rare disease royalty. Genzyme's Cerezyme and Fabrazyme franchises provided durable orphan drug revenue, and the CVR structure gave Sanofi downside protection.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sanofi shareholders grew nervous about negotiating a higher price for Genzyme, fearing overpayment. The CVR mechanism added uncertainty investors found…
Sanofi-aventis and Genzyme Corporation today announced that they have entered into a definitive merger agreement under which sanofi-aventis will acquire…
Manufacturing failures at Allston Landing plant forced Cerezyme and Fabrazyme supply cuts, missing CVR milestones and deflating contingent value rights held by…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Sanofi-aventis acquired Genzyme Corporation for approximately $20.1 billion ($74.00 per share in cash plus one Contingent Value Right per share), gaining a leading rare disease portfolio including Cerezyme, Fabrazyme, and the multiple sclerosis candidate Lemtrada (alemtuzumab).
400K US cases/yr · $12.0B US MS Therapeutics Market (2011)
Multiple sclerosis affects ~400,000 Americans. Genzyme's Lemtrada (alemtuzumab) was in Phase III for relapsing MS, representing a high-efficacy but high-risk therapy. The MS market was expanding with new oral therapies.
MS treatment in 2011 featured interferons, glatiramer acetate, and new entrants: fingolimod (Gilenya, 2010), natalizumab (Tysabri). Lemtrada was approved in 2014 with a restricted label. The market shifted toward high-efficacy therapies, with ocrelizumab (Ocrevus, 2017) eventually dominating.
10K US cases/yr · $2.0B Global Rare ERT Market (2010)
Fabry disease (~8,000 US patients) and Pompe disease (~2,000 US patients) are rare lysosomal storage disorders treated with enzyme replacement therapy. Genzyme's Fabrazyme and Myozyme/Lumizyme were the standard of care with combined revenue exceeding $700M.
Fabrazyme competed with Shire's Replagal in Europe but had exclusive US access. Pompe disease had no direct competitors. The 2009 manufacturing crisis opened the door for competitors. Gene therapies were years away.
6K US cases/yr · $1.5B Global Gaucher Treatment Market (2010) · $793M Cerezyme Global Revenue (2010)
Gaucher disease is a rare lysosomal storage disorder affecting ~6,000 US patients. Genzyme's Cerezyme was the gold-standard enzyme replacement therapy generating ~$793M in 2010. The acquisition gave Sanofi leadership in rare disease with strong pricing power.
Cerezyme dominated the Gaucher market but faced disruption from a 2009 manufacturing contamination. Shire's Vpriv (2010) and Pfizer's Elelyso (2012) entered as alternatives. Oral substrate reduction therapy (eliglustat/Cerdelga) was in Genzyme's pipeline.
Sanofi-aventis and Genzyme announce definitive agreement for Sanofi to acquire Genzyme at $74/share (~$20.1B) plus contingent value rights (CVRs) tied to Lemtrada milestones.
Sanofi commences tender offer for all outstanding Genzyme shares at $74/share in cash, aiming to resolve months of negotiation after an initial unsolicited approach in 2010.
Exchange offer expires with 224.5M shares tendered (84.6% of outstanding), exceeding the minimum condition. Subsequent offering period opens April 4-7.
Sanofi effects short-form merger to complete Genzyme acquisition. CVRs begin trading on Nasdaq under ticker GCVRZ, tied to Lemtrada (alemtuzumab) and production milestones.
Genzyme contributes EUR 2.395B in consolidated sales (from April 1, 2011), led by Cerezyme (EUR 441M) and Fabrazyme (EUR 109M) as rare disease supply normalizes.
Genzyme unit delivers 16.9% revenue growth in 2012 as Cerezyme returns to full production after contamination crisis and Fabrazyme supply stabilizes globally.
EU approves Lemtrada (alemtuzumab) for relapsing-remitting MS, triggering CVR milestone payments and validating a key element of the acquisition thesis.
Sanofi acquired Genzyme at a premium after a protracted negotiation but built a durable rare-disease franchise (Cerezyme, Fabrazyme, Myozyme) that now anchors its Specialty Care division. The CVR structure bridged the valuation gap on Lemtrada. Genzyme revenue grew steadily post-acquisition and the rare disease platform has been strategically differentiated vs. mass-market pharma peers.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Genzyme Corporation (this deal) | 2011 | $20.1B | 84 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 2011 deals · Sanofi SA deals · Metabolic deals